IMR Press / EJGO / Volume 31 / Issue 1 / pii/1630984349032-1474177823

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Case Report
Primary malignant mixed müllerian tumour of the fallopian tube. Report of a case
Show Less
1 Department of Pathology, Tzaneion General Hospital of Piraeus, General Hospital of Larissa
2 Department of Anesthesiology, General Hospital of Larissa (Greece)
Eur. J. Gynaecol. Oncol. 2010, 31(1), 126–128;
Published: 10 February 2010
Abstract

Malignant mixed mullerian tumour of the fallopian tube is an extremely rare lesion and to date only approximately 50 cases have been reported. The tumour is seldom distinguished preoperatively from other more common lesions or ovarian cancer. We report a case of a 60-year-old woman who presented to our hospital with pelvic pain. There was no clinical evidence of ascites or adenopathy. Ultrasound and abdominal and pelvic computed tomography showed a left adnexal mass. Total abdominal hysterectomy and bilateral salpingo-oophorectomy were carried out. Grossly the left side of the fallopian tube was dilated and the cut surface revealed a solid mass filling the entire lumen. Histological examinations showed a malignant mixed mullerian tumour. The tumor was an admixture of both carcinomatous and sarcomatous elements. The carcinomatous element was composed of well to moderately differentiated squamous cell carcinoma and the sarcomatous component was made up of anaplastic spindle shaped cells with hyperchromatic nuclei. An immunohistochemical study was performed. The patient was admitted to the anticancer hospital for further treatment. The prognosis of a primary malignancy of the fallopian tube is poor and depends more on staging than on histologic type and grade.
Keywords
Fallopian tube
Mixed müllerian tumour
Immunohistochemistry
Share
Back to top